Quarterly report pursuant to Section 13 or 15(d)

Convertible Securities - Additional Information (Detail)

v2.4.0.6
Convertible Securities - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended
Jun. 30, 2012
Jun. 30, 2012
Jun. 30, 2012
Secured Promissory Note
Installment
Dec. 31, 2011
Secured Promissory Note
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Series GG Warrants
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Upon FDA approval of Lymphoseek
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable One
Potentially available on terms to be negotiated
Jun. 30, 2012
Secured Promissory Note
Promissory Notes Payable Two
At the time of product registration or upon commercial sales
May 31, 2011
Series B Preferred Stock
Jun. 30, 2012
Series B Preferred Stock
Dec. 31, 2011
Series B Preferred Stock
Debt Instrument                        
Number of shares of convertible preferred stock converted                   917    
Number of common stock issued up on conversion                   2,998,590    
Preferred stock, shares outstanding                     9,083 9,083
Number of common stock issuable up on future conversion 29,701,410 29,701,410                    
Loan Agreement, maximum borrowing capacity       $ 10,000,000 $ 7,000,000       $ 3,000,000      
Debt instrument, interest rate             6.75%          
Debt instrument, effective interest rate               10.00%        
Warrants to purchase common stock, shares 17,500,000 17,500,000       333,333            
Warrants to purchase common stock, exercise price           2.10            
Warrants to purchase common stock, expiration period           2016-12            
Principal and interest, monthly installments period     30                  
Debt instrument, maturity date         Dec. 01, 2014              
Debt instrument, conversion face amount     1,500,000                  
Convertible debt, fixed conversion price     $ 2.77                  
Option to convert debt to common stock beneficial conversion feature     1,500,000   24,888              
Amortization of the debt discounts and deferred financing costs $ 144,000 $ 260,000